Genetic Screening – NexCCS

nexccsNexCCS is the most advanced and validated embryo screening platform available for in vitro fertilization (IVF) today.

Validated over several years and multiple rigorous clinical trials, NexCCS can accurately determine if an embryo possesses the right number of chromosomes (euploidy) or too few or too many (aneuploidy). This is important because aneuploidy is the leading cause of IVF failure. Published data also suggests that 50-70% of miscarriages are due to aneuploidy. Selection with NexCCS can substantially reduce these risks.

NexCCS is owned and operated by the Foundation for Embryonic Competence (FEC). All proceeds from NexCCS testing go directly to the FEC and are used to support research and education. Learn more about the Foundation at feclabs.org.

FEATURES OF THE NEXCCS PROCESS:

  • Greater than 98% accuracy1
  • Ability to detect more subtle abnormalities in embryos, such as mosaicism and segmental abnormalities2
  • 69% delivery rate in a large-scale clinical trial3

ONE HEALTHY EMBRYO, ONE HEALTHY BABY

In the U.S., approximately half of all babies conceived following IVF were born as part of a twin or triplet pregnancy. These pregnancies typically result from a multiple embryo transfer and are associated with a significantly increased risk of problems for the mother and baby.

Utilizing NexCCS to choose the single best embryo for transfer makes the promise of Single Embryo Transfer (SET) a reality and provides a safer and more effective treatment option for many patients.

UNCOMPROMISED RESULTS

  • High singleton success rates demonstrated in RMANJ’s BEST (Blastocyst Euploid Selective Transfer) Trial.4

FEWER COMPLICATIONS

  • Combining NexCCS and SET can reduce the risks of miscarriage and complications associated with multiple deliveries.
  1. Werner MD, Franasiak JM, Hong KH, Juneau CR, Tao X, Landis J, Upham KM, Treff NR, Scott RT. A prospective, blinded, non-selection study to determine the predictive value of ploidy results using a novel method of targeted amplification based Next generation sequencing (NGS) for comprehensive chromosome screening (CCS).  Fertil Steril 2015; 104 (3): Suppl: e12-13.
  2. Morin SJ, Tiegs A, Jalas C, Landis J, Zhan Y, Neal S, Franasiak J, Scott RT Jr. Higher resolution aneuploidy screening with targeted NGS may increase the pool of transferrable embryos despite inclusion of segmental and mosaic range diagnostic categories.  European Society for Human Reproduction and Embryology Annual Meeting. Barcelona, Spain.  July 2018
  3. Marin D, Sun L, Scott RT Jr., Treff N.  Increased implantation rates with targeted next generation sequencing (TNGS) compared to QPCR-based comprehensive chromosome screening.  Fertil Steril 2017; 108 (3); Suppl: e271.
  4. Forman, E.J., Hong, K.H., Ferry, K.M., Tao, X., Treff, N.R., Scott, R.T. Blastocyst euploid selective transfer (BEST): an RCT of comprehensive chromosome screening- single embryo transfer (CCS-SET) vs double embryo transfer (DET)- equivalent pregnancy rates, eliminates twins. Fertil Steril 2012; 98: S49.

For more information about genetic screenings and CCS, reach out to us today.